Evidence-based Guideline for Therapeutic Drug Monitoring of Vancomycin: 2020 Update by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society
Na He,Shan Su,Zhikang Ye,Guanhua Du,Bei He,Dakui Li,Youning Liu,Kehu Yang,Xianglin Zhang,Yingyuan Zhang,Xiao Chen,Yaolong Chen,Zhigang Chen,Yalin Dong,Guang Du,Jian Gu,Daihong Guo,Ruichen Guo,Xin Hu,Zheng Jiao,Huande Li,Gaolin Liu,Zhiping Li,Yuan Lv,Wei Lu,Liyan Miao,Jieming Qu,Tieying Sun,Rongsheng Tong,Li Wang,Minggui Wang,Rui Wang,Aidong Wen,Jiuhong Wu,Xin’an Wu,Yingchun Xu,Yong Yang,Fan Yang,Siyan Zhan,Bikui Zhang,Chao Zhang,Huizhi Zhang,Jie Zhang,Jing Zhang,Jun Zhang,Wenting Zhang,Libo Zhao,Limei Zhao,Rongsheng Zhao,Wei Zhao,Zhigang Zhao,Wei Zhou,Xian-Tao Zeng,Suodi Zhai
DOI: https://doi.org/10.1093/cid/ciaa1536
IF: 20.999
2020-11-15
Clinical Infectious Diseases
Abstract:Abstract Background Clinical practice guidelines or recommendations often require timely and regular updating as new evidence emerges, because this can alter the risk-benefit trade-off. The scientific process of developing and updating guidelines accompanied by adequate implementation can improve outcomes. To promote better management of patients receiving vancomycin therapy, we updated the guideline for the therapeutic drug monitoring (TDM) of vancomycin published in 2015. Methods Our updated recommendations complied with standards for developing trustworthy guidelines, including timeliness and rigor of the updating process, as well as the use of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. We also followed the methodology handbook published by the National Institute for Health and Clinical Excellence and the Spanish National Health System. Results We partially updated the 2015 guideline. Apart from adults, the updated guideline also focuses on pediatric patients and neonates requiring intravenous vancomycin therapy. The guideline recommendations involve a broadened range of patients requiring TDM, modified index of TDM (both 24-hour area under the curve and trough concentration), addition regarding the necessity and timing of repeated TDM, and initial dose for specific subpopulations. Overall, 1 recommendation was deleted and 3 recommendations were modified. Eleven new recommendations were added, and no recommendation was made for 2 clinical questions. Conclusions We updated an evidence-based guideline regarding the TDM of vancomycin using a rigorous and multidisciplinary approach. The updated guideline provides more comprehensive recommendations to inform rational and optimized vancomycin use and is thus of greater applicability.
immunology,infectious diseases,microbiology